DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Information source: Forest Laboratories
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Major Depressive Disorder

Intervention: Escitalopram (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Forest Laboratories

Official(s) and/or principal investigator(s):
Suneeta Ahuja, PhD, Study Chair, Affiliation: Forest Laboratories

Summary

This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).

Clinical Details

Official title: An Open-label Long-term Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder

Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Patients With Any Treatment Emergent Adverse Events (TEAEs)

Eligibility

Minimum age: 7 Years. Maximum age: 11 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female outpatients 7 to 11 years of age, inclusive

- Current diagnosis of MDD based on DSM-IV-TR (Diagnostic and Statistical Manual of

Mental Disorders, Fourth Edition, Text Revision) criteria as confirmed by K-SADS-PL (Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime) with a minimum duration of 6 weeks

- Patient's parent(s), guardian(s), or LAR(s) is capable of providing information about

his or her condition, provides informed consent, and agrees to accompany the patient to all study visits. (Preferably the same parent, guardian, or LAR will accompany the patient to all study visits)

- Patient's family is sufficiently organized and stable to guarantee adequate safety

monitoring Exclusion Criteria:

- Current principal DSM-IV-TR-based diagnosis of an axis I disorder other than MDD that

was the primary focus of treatment

- Patients with a diagnosis of conduct disorder will not be allowed to participate in

this study

- Current diagnosis of mental retardation, dementia, or amnestic or other cognitive

disorders based on DSM-IV-TR criteria

- History of allergy, intolerance, or hypersensitivity to escitalopram, citalopram, or

other drugs of the same class

- Imminent risk of injuring self or others or causing significant damage to property,

as judged by the PI

- Suicide risk as determined by meeting any of the following criteria:

- Any suicide attempt

- Significant risk, as judged by the PI, based on the psychiatric interview or

information collected in the Columbia-Suicide Severity Rating Scale (C-SSRS)

Locations and Contacts

Forest Investigative Site 001, Dothan, Alabama 36303, United States

Forest Investigative Site 006, San Diego, California 92108, United States

Forest Investigative Site 018, Santa Ana, California 92701, United States

Forest Investigative Site 008, Washington, District of Columbia 20010-2970, United States

Forest Investigative Site 013, Jacksonville Beach, Florida 32250, United States

Forest Investigative Site 017, Atlanta, Georgia 30308, United States

Forest Investigative Site 004, Overland Park, Kansas 66211, United States

Forest Investigative Site 011, Creve Coeur, Missouri 63141, United States

Forest Investigative Site 007, Omaha, Nebraska 68131, United States

Forest Investigative Site 002, Cleveland, Ohio 44106, United States

Forest Investigative Site 012, Oklahoma City, Oklahoma 73116, United States

Forest Investigative Site 003, Philadelphia, Pennsylvania 19139, United States

Forest Investigative Site 010, Dallas, Texas 75235, United States

Forest Investigative Site 014, Clinton, Utah 84015, United States

Forest Investigative Site 005, Bellevue, Washington 98007, United States

Forest Investigative Site 015, Kirkland, Washington 98033, United States

Additional Information

Starting date: September 2010
Last updated: January 31, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017